August 22, 2023 : The Advent of the New Drug Lecanemab
© 安岡喜晴 (JoyShine)
Lecanemab, a drug for Alzheimer's disease jointly developed by Eisai and Biogen, was approved yesterday by the Ministry of Health, Labor and Welfare.
Previously, a drug for symptomatic treatment had been approved, but this "Lecanemab" is the first drug to act directly on the substance in the brain believed to be the cause of the disease.
Recanemab is only used for patients with mild Alzheimer's disease or "mild cognitive impairment," the stage before dementia sets in.
The problem is the price of the drug, which can't be too high to make it more widely available,
and I think the drugs, community activities, and nutrients in the diet should be combined appropriately to achieve the best treatment,
and how the importance of each factor will change with the advent of the new drug is what we will see in the near future,
the drug that can be used in the early stages gives us hope, and the increasing number of medical professionals interested in treating the disease could lead to drastic advances in technology in this field.
Today I went to Nagaokakyo City to attend a meeting of the safety and health committee.
Nagaokakyo City is close to where I was born and raised, and every time I come here I feel a little nostalgic.
I used to come here often, riding in my parents' car, going to restaurants with my family, or visiting the stores they owned.
This area is full of my old memories.